Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
At close: 02:28PM EST
Advertisement

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln 4133
Switzerland
41 61 906 89 50
https://www.santhera.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Mr. Dario EklundChief Exec. Officer731.41kN/A1968
Dr. Thomas Meier Ph.D.Founder & Director97.18kN/A1962
Mr. Andrew P. SmithChief Financial Officer479.45kN/A1963
Mr. Oliver StrubExec. VP, Gen. Counsel & Sec.N/AN/A1963
Mr. Günther MetzHead of Bus. Devel. & Exec. VPN/AN/A1958
Eva KaliasHead of External CommunicationsN/AN/AN/A
Mr. Shabir HashamHead of the Puldysa Global ProgramN/AN/AN/A
Ms. Stephanie Brown B.Sc., M.B.A.Pres of North AmericaN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidate include vamorolone, which is being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It has collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.

Corporate Governance

Santhera Pharmaceuticals Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement